55304-72-8

Basic information

• Product Name: 2,3,6-Trichloro-5-nitro-pyridine
• Synonyms: 2,3,6-Trichloro-5-nitro-pyridine
• CAS NO: 55304-72-8
• Molecular Formula: C₅HCl₃N₂O₂
• Molecular Weight: 227.43264
• Mol File: 55304-72-8.mol
• Article Data: 4

Chemical Properties

• Melting Point: 69-71 °C
• Boiling Point: 301.1±37.0 °C(Predicted)
• Appearance: /
• Density: 1.744±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -8.15±0.10(Predicted)
• CAS DataBase Reference: 2,3,6-Trichloro-5-nitro-pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3,6-Trichloro-5-nitro-pyridine(55304-72-8)
• EPA Substance Registry System: 2,3,6-Trichloro-5-nitro-pyridine(55304-72-8)

Safety Data

• Hazardous Substances Data: 55304-72-8(Hazardous Substances Data)

Usage

General Description

2,3,6-Trichloro-5-nitro-pyridine is a chemical compound with the molecular formula C5HCl3N2O2. It is a yellow crystalline solid that is primarily used as an intermediate in the synthesis of various organic compounds, including pharmaceuticals, pesticides, and dyes. This chemical is classified as a nitro compound, containing a nitro group (-NO2) and a pyridine ring, which makes it useful in the production of a wide range of products. However, it is important to handle this compound with caution, as it is toxic and may cause skin and eye irritation, and it can also be harmful if ingested or inhaled. Safety precautions should be followed when working with 2,3,6-Trichloro-5-nitro-pyridine to prevent exposure and minimize potential health risks.

Upstream product

• 6515-09-9 2,3,6-trichloropyridine 
• 7664-93-9 sulfuric acid 

Downstream Products

• 136888-28-3 3-amino-2-bis(ethoxycarbonyl)methyl-5,6-dichloropyridine 
• 136888-26-1 5,6-dichloro-4-azaoxindole 

Relevant articles and documents

FUSED IMIDAZOLE COMPOUNDS

The present invention provides compounds represented by formula (I), pharmaceutically acceptable salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof (wherein the characters are as defined in the description). The compounds represented by formula (I) have affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 (GABAA α5) and act as GABAA α5 negative allosteric modulators (GABAA α5 NAM), so that they are useful in the prevention and/or treatment of diseases which are related to the GABAA α5 such as Alzheimer's disease.

NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHIBITORS

The present invention describes new pyrazolo-pyrimidine derivatives of formula (I) or a pharmaceutically acceptable salt thereof; (I) wherein, R1 is halogen, cyano, or C1-C3alkyl optionally substituted by halogen; R2 is C1-C6alkyl optionally substituted one or more times by C1-C6alkyl, C2-C6alkenyl, hydroxyl, N,N-di-C1-C6alkyl amino, N-mono-C1-C6alkyl amino, O-Rg, Rg, phenyl, or by C1-C6alkoxy wherein said alkoxy again may optionally be substituted by C1-C6alkoxy, N,N-di-C1-C6alkyl amino, Rg or phenyl; C3-C6cycloalkyl optionally substituted by C1-C6alkyl, N,N-di-C1-C6alkyl amino or C1-C6alkoxy-C1-C6alkyl, and/or two of said optional substituents together with the atoms to which they are bound may form an annulated or spirocyclic 4 - 6 membered saturated heterocyclic ring comprising 1 - 2 O atoms; phenyl optionally substituted by C1-C6alkoxy; a 5 - 6 membered heteroaryl ring having 1 to 3 heteroatoms selected from N and O said ring being optionally substituted by C1-C6alkyl which may be optionally substituted by amino or hydroxy; Rg; or N,N-di-C1-C6alkyl amino carbonyl; and R is phenyl independently substituted two or more times by Ra, 2-pyridyl independently substituted one or more times by Rb, 3-pyridyl independently substituted one or more times by Rc, or 4-pyridyl independently substituted one or more times by Rd; which are generally interacting with MALT1 proteolytic and/or autoproteolytic activity, and in particular which may inhibit said activity. The present invention further describes the synthesis of said new pyrazolo-pyrimidine derivatives, their use as a medicament, especially by interacting with MALT1 proteolytic and/or autoproteolytic activity.